GCORE
6.3.2024 09:06:31 CET | Business Wire | Press release
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the acquisition of StackPath’s web application and API protection (WAAP) solution. A highly regarded security product for protecting applications, the new acquisition will provide Gcore customers with an enhanced, enterprise-grade security solution, incorporating web application firewall (WAF), API security, bot protection, and Layer-7 DDoS mitigation at the edge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306076612/en/
Gcore is the global edge AI, cloud, network, and security solutions provider. (Graphic: Gcore)
The acquisition marks a pivotal advancement in Gcore’s mission to deliver comprehensive, edge security services to its customers worldwide. The WAAP will be integrated into Gcore’s security product lineup by Q3 2024.
StackPath WAAP was recognised as a cloud WAF leader by independent security solutions assessor, SecureIQLab in a report comparing the security and operational efficiency of multiple cloud WAF solutions.
Andre Reitenbach, CEO at Gcore, comments: “The acquisition of StackPath WAAP marks a significant milestone in our strategic roadmap, underscoring our commitment to continuous innovation of our solutions and edge infrastructure. With its outstanding reputation for quality, StackPath WAAP stands as a premier solution in the market. Its integration will further strengthen our customers’ application and API security and provide them with enhanced defences against application-layer DDoS attacks at the edge”.
Gcore’s extensive edge network spans over 160 points of presence, delivering fast, reliable, and secure digital experiences worldwide. By leveraging its edge network, Gcore brings protection closer to the end user. This approach reduces latency, scales seamlessly against large-scale DDoS attacks, protects against common vulnerabilities, safeguards critical API endpoints, and leverages real-time threat intelligence. A key advantage of StackPath WAAP is its ability to leverage machine learning to detect and mitigate malicious behaviour. As Gcore incorporates the product into its portfolio, it will enhance its capabilities with AI-driven WAF, enabling advanced identification of HTTP patterns to provide enhanced protection and improve mitigation for zero-day attacks.
Gcore will maintain the rapid setup and out-of-the-box features that have made StackPath WAAP easily configurable, and add capabilities including customisation, advanced threat identification, and real-time analytics. Integration is scheduled by Q3 2024, with an early-access version available for customer evaluation in the meantime. Flexible pricing plans will meet the needs of customers based on usage.
“We’re passionate about security in the cloud and proud of the WAAP we built at StackPath,” said Kip Turco, Chief Executive Officer for StackPath. “When we decided to focus even more specifically on our latency-sensitive, highly distributed edge-computing platform, we knew Gcore would be the perfect home for the continuing innovation of this next-gen WAAP. We look forward to partnering with Gcore even more in the ongoing evolution of cloud, edge, and the security solutions the industry needs.”
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, Gcore manages its own IT infrastructure across six continents, with leading network performance in Europe, Africa, and LATAM.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306076612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom